Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 198-200

  Bacigalupo, A ^a   Marsh, J C W ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

aplastic anaemia; HSCT

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TISSUE TYPING; UNRELATED DONORS;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84873428785     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.233     Document Type: Review

References (19)

1. Maury S, Balere-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K et al. French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: Improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589-596
2. Viollier R, Socié G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41: 45-50
3. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Blood 2002; 100: 799-803
4. Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215
5. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947-950
6. Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. For the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, (SAA WP-EBMT). Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976-982
7. Gupta V, Ball S, Sage D, Ortin M, Freires M, Gordon-Smith E et al. Marrow transplants from matched unrelated donors for aplastic anemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467-471
8. Siegal D, Xu W, Sutherland R, Kuruvilla J, Lipton JH, Minden M et al. Graftversus- host disease following marrow transplantation for aplastic anemia: Different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008; 42: 51-56
9. Gupta V, Ball S, Yi Q, Sage D, McCann S, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti- CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biolo Blood Marrow Transplant 2004; 10: 867-876
10. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland R, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351-2357
11. Dufour C, Bacigalupo A, Socie G, Tichelli A, Risitano AM, Schrezenmeier H et al. European Blood and Marrow Transplant Group, Severe Aplastic Anemia. Rabbit ATG for aplastic anemia treatment: A backward step? Lancet 2011, doi: 10.1016/ S0140-6736(11)60817-9
12. Bacigalupo A. Back to the OR? Blood 2001; 118: 2386
13. Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 2012; 47: 101-106
14. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583
15. Takakazu K, Yasuo M, Keitaro M, Koichi K, Hidetoshi I, Hiroh S et al. For The Japan Marrow Donor Program. High-risk HLA alleles mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110: 2235-2241
16. Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S et al. Gruppo Italiano Trapianto di Midollo Osseo, Cellule Staminale Ematopoietiche (CSE) e Terapia Cellulare; Italian Bone Marrow Donor Registry. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009; 114: 1437-1444
17. Eapen M, Rademacher JL, Antin JH, Champlin RE, Carreras J, Fay J et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118: 2618-2621
18. Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T et al. Rituximab treatment for epstein-barr virus dnaemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 901-907
19. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12: 1277-1284